Pulmatrix, Inc. (NASDAQ: PULM) announced a definitive merger agreement with Eos SENOLYTIX, Inc., a biotechnology company focused on gerotherapeutic peptides that target mitochondrial dysfunction. Under the deal, Pulmatrix will acquire Eos and the combined entity will operate under the name Eos SENOLYTIX, Inc., trading on Nasdaq under the ticker "EOSX."
The transaction is supported by a $19 million financing package. Pulmatrix will receive a $1 million investment from RCM Eos PIPE HOLDINGS LLC, while Eos will receive a bridge component from RCM Eos Holdings, LLC. Both investments are managed by Rapha Capital Management, LLC, and the combined proceeds are intended to fund the development of Eos’s MitoXcel™ platform and its lead clinical candidate, PTC‑2105, for sarcopenia and sarcopenic obesity.
Pulmatrix’s pivot from its original inhaled drug development focus to acquiring a company with a mitochondrial‑targeted platform reflects a strategic shift toward the emerging gerotherapeutics market. Eos’s MitoXcel™ platform uses AI‑driven peptide design to target mitochondrial dysfunction and senescent cells, positioning PTC‑2105 as a potential alternative to GLP‑1 receptor agonists for obesity and muscle wasting. The merger is expected to accelerate the clinical development of PTC‑2105 and broaden the combined company’s pipeline in a market that is projected to grow as the global population ages.
Prior to the merger, Pulmatrix reported a year‑ended December 31, 2025 revenue of nil, down from $7.8 million in the 2024 year. Cash and cash equivalents stood at $4.1 million versus $9.5 million at the end of 2024, and the company’s market capitalization was $7.74 million. Shares had fallen 68.5% over the past year, underscoring investor concerns about Pulmatrix’s standalone prospects and the need for a strategic partnership.
Market reaction to the announcement was negative, with Pulmatrix shares falling sharply and crossing below the five‑day moving average. The steep decline reflects investor concerns about the significant dilution for existing Pulmatrix shareholders—who will own only about 6% of the combined company—and the company’s prior financial challenges.
Management commentary highlighted the strategic rationale for the deal. Kevin Slawin, M.D., CEO of Eos SENOLYTIX, said the merger “represents an important step forward in advancing our mission to develop therapies that target the root causes of aging‑related disease, positioning our MitoXcel gerotherapeutic platform to advance PTC‑2105 and our broader pipeline toward clinical development.” Peter B. Ludlum, CEO of Pulmatrix, noted that the transaction provides stockholders the opportunity to participate in a company addressing diseases with unmet medical need.
Pulmatrix had previously pursued a merger with Cullgen Inc., which was terminated, prompting the company to seek alternative opportunities. Eos’s platform is built on proprietary AI‑driven peptide design, and the company’s lead candidate, PTC‑2105, is positioned to address sarcopenia and sarcopenic obesity—conditions that lack effective treatments and represent a significant unmet medical need. The combined company aims to become a leader in the gerotherapeutics market, which is expected to expand as the population ages and obesity rates rise.
The parties anticipate closing the transaction in mid‑2026, subject to customary conditions such as shareholder approval and regulatory filings.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.